Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
News May 06, 2014
Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
How Do Plants Avoid UV Damage?News
Public health warnings against too much exposure to UV are based on sound advice: UV rays can damage DNA and cause cancers and other diseases. Plants, however, cannot avoid UV. A new study now shows how plants' DNA repair system helps combat constant UV exposure.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018